Photodynamic therapy for choroidal neovascular disease: Photosensitizers and clinical trials

Ophthalmology Clinics of North America

Volumn 15, Issue 4, 2002, Pages 473-478

  Lim, Jennifer I ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; LUTETIUM TEXAPHYRIN; PHOTOSENSITIZING AGENT; PURPURIN DERIVATIVE; TALAPORFIN; TIN DERIVATIVE; TIN ETHYL ETIOPURPURIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MYOPIA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 0036950994     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-1549(02)00044-5     Document Type: Review

References (26)

1. Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 1997;14:323-8.
2. Husain D, Miller JW, Kenney AG, Michaud N, Flotte TJ, Gragoudas ES. Photodynamic therapy and digital angiography of experimental iris neovascularization using liposomal benzoporphyin derivative. Ophthalmology 1997;104:1242-50.
3. Hausmann WH. Die sensibilisierende wirkung des hamatoporphyrins. Biochem Z 1911;30:276-316.
4. Castellani A, Page GP, Concioli M. Photodynamic effect of haematoporphyrin on blood microcirculation. J Pathol Bacteriol 1963,86:99-102.
5. Miller H, Miller B. Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch Ophthalmol 1993;111:855-60.
6. Richter AM, Waterfield E, Jain AK, et al. Photosensitising potency of structural analogues of benzoporhyrin derivative (BPD) in a mouse tumor model. Br J Cancer 1991;63:87-93.
7. Richter AM, Cerruti- Sola S, Stemberg ED, Dolphin D, Levy JG. Biodistribution of tritiated benzophorphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol 1990;5:231-44.
8. Allison BA, Waterfield E, Richter AM, Levy JG. The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. Photochem Photobiol 1991;54: 709-15.
9. Richter AM, Waterfield E, Jain AK, Canaan AJ, Allison BA, Levy JG. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD) to tumor tissue in a mouse tumor model. Photochem Photobiol 1993;57:1000-6.
10. Schmidt-Erfurth U, Bauman W, Gragoudas E, Flotte TJ, Michaud NA, Birngruber R, et al. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 1994;101:89-99.
11. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994;101:1953-61.
12. Miller JW, Walsh AW, Kramer M, Hasan T, Michaud N, Flotte TJ, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 1995; 113:810-8.
13. Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES, et al. Effects of photodynamic therapy using verteporphyrin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 1999;40:2322-31.
14. Graham KB, Arbour JD, Connolly EJ, Delori F, Carson D, Gragoudas ES, et al. Digital angiography using lutetium texaphyrin in a monkey model of choroidal neovascularization [abstract]. Invest Ophthalmol Vis Sci 1999;40:402.
15. Blumenkranz MS, Woodbum KW, Qing F, Verdooner S, Kessel D, Miller R. Lutetium texaphyrin (Lu-Tex): A potential new agent for ocular fundus angiography and photodynamic therapy. Am J Ophthalmol 2000;129: 353-62.
16. Arbour JD, Connolly EJ, Graham K, Carson D, Michaud N, Flotte T, et al. Photodynamic therapy of experimental choroidal neovascularization using intravenous infusion of lutetium texaphyrin [abstract]. Invest Ophthalmol Vis Sci 1999;40:401.
17. Primbs GB, Casey R, Wamser K, Snyder WJ, Crean DH. Photodynamic therapy for corneal neovascularization. Ophthalmic Surg Lasers 1998;29:832-8.
18. Mori K, Yoneya S, Anzail K, et al. Photodynamic therapy of experimental choroidal neovascularization with a hydrophilic photosensitizer mono-L-aspartyl chlorin 6. Retina 2001;21:499-508.
19. Nakashizuka T, Mori K, Hayashi N, et al. Retreatment effect of NPe6 photodynamic therapy on the normal primate macula. Retina 2001;21:493-8.
20. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of a single treatment in a phase I and II study. Arch Ophthalmol 1999; 117:1161-73.
21. Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1177-87.
22. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol 1999;117: 1329-45.
23. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001;119: 198-207.
24. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology 2001;108: 841-52.
25. Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration. Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-59.
26. Sickenberg M, Schmidt Erfurth U, Miller JW, Pournaras CJ, Zografos L, Piguet B, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks and idiopathic causes. Arch Ophthalmol 2000;18:327-36.